Metabolic improvements due to GBR that may be beneficial in the management of type 2 diabetes include better glycemic control [13, 44–48, 51, 52, 55, 56], correction of dyslipidemia [46, 49, 51, 52, 54, 55, 57], amelioration of oxidative stress [40, 58], reduced type 1 tissue plasminogen activator inhibitor (PAI-1) [45, 56], and increased sodium potassium adenosine triphosphatase and homocysteine thiolactonase activities [50, 58]. Here, SERPINE1 is linked to metabolic syndrome.